565 Midterm Exam content
domains
—including pharmacokinetics/pharmacodynamics, autonomic
nervous system pharmacology, cardiovascular pharmacology,
respiratory pharmacology, endocrine pharmacology, pain
management and opioid stewardship, psychiatric
pharmacology, drug interactions, patient education, and
legal/ethical/DEA regulations—found in the search results.
Each question includes a correct answer and a detailed
evidence-based rationale aligned with Chamberlain
University curriculum standards.
SECTION I: Pharmacokinetics & Pharmacodynamics (Q1–35)
1. Which pharmacokinetic process describes the movement of a
drug from the site of administration into the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Answer: C
Rationale: Absorption is the process by which a drug enters the
,systemic circulation from its site of administration. Distribution,
metabolism, and excretion follow absorption.
2. What is the primary site of drug metabolism for most oral
medications?
A. Kidney
B. Liver
C. Lung
D. Small intestine exclusively
Answer: B
Rationale: The liver contains high concentrations of cytochrome
P450 enzymes responsible for Phase I and Phase II metabolism of
the majority of drugs.
3. Which term describes the fraction of an administered drug that
reaches the systemic circulation unchanged?
A. Bioavailability
B. Half-life
C. Clearance
D. Volume of distribution
Answer: A
Rationale: Bioavailability describes the extent and rate at which
the active drug moiety enters systemic circulation. Intravenous
administration has 100% bioavailability.
4. A patient with liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. What should the NP
anticipate?
,A. A decreased therapeutic effect
B. An increased risk of toxicity
C. No change in drug response
D. Rapid excretion of the drug
Answer: B
Rationale: Cirrhosis impairs first-pass metabolism, leading to
higher plasma concentrations of the drug and an increased risk of
toxicity.
5. Which parameter reflects the time required for the plasma
concentration of a drug to decrease by 50%?
A. Onset of action
B. Duration of action
C. Half-life
D. Therapeutic index
Answer: C
Rationale: Half-life is the time it takes for the amount of drug in
the body to be reduced by one-half. It determines the dosing
interval.
6. A drug with a narrow therapeutic index requires:
A. Routine monitoring of serum drug levels
B. High doses to achieve therapeutic effect
C. No monitoring due to its safety profile
D. Administration without regard to timing
Answer: A
Rationale: A narrow therapeutic index means the difference
, between therapeutic and toxic doses is small. Serum levels must
be monitored to ensure safety and efficacy.
7. Which term refers to the ratio of the dose that produces
toxicity to the dose that produces a therapeutic effect?
A. Bioavailability
B. Therapeutic index
C. Half-life
D. Clearance
Answer: B
Rationale: The therapeutic index is a measure of drug safety. A
higher therapeutic index indicates a safer drug.
8. What is the primary focus of pharmacokinetics in drug therapy?
A. The study of drug effects on the body
B. The study of drug absorption, distribution, metabolism, and
excretion
C. The study of drug toxicity and adverse effects
D. The study of drug-receptor interactions
Answer: B
Rationale: Pharmacokinetics focuses on what the body does to
the drug—the processes of Absorption, Distribution, Metabolism,
and Excretion (ADME). Pharmacodynamics is what the drug does
to the body.
9. How does the first-pass effect influence oral drug
bioavailability?
domains
—including pharmacokinetics/pharmacodynamics, autonomic
nervous system pharmacology, cardiovascular pharmacology,
respiratory pharmacology, endocrine pharmacology, pain
management and opioid stewardship, psychiatric
pharmacology, drug interactions, patient education, and
legal/ethical/DEA regulations—found in the search results.
Each question includes a correct answer and a detailed
evidence-based rationale aligned with Chamberlain
University curriculum standards.
SECTION I: Pharmacokinetics & Pharmacodynamics (Q1–35)
1. Which pharmacokinetic process describes the movement of a
drug from the site of administration into the bloodstream?
A. Distribution
B. Metabolism
C. Absorption
D. Excretion
Answer: C
Rationale: Absorption is the process by which a drug enters the
,systemic circulation from its site of administration. Distribution,
metabolism, and excretion follow absorption.
2. What is the primary site of drug metabolism for most oral
medications?
A. Kidney
B. Liver
C. Lung
D. Small intestine exclusively
Answer: B
Rationale: The liver contains high concentrations of cytochrome
P450 enzymes responsible for Phase I and Phase II metabolism of
the majority of drugs.
3. Which term describes the fraction of an administered drug that
reaches the systemic circulation unchanged?
A. Bioavailability
B. Half-life
C. Clearance
D. Volume of distribution
Answer: A
Rationale: Bioavailability describes the extent and rate at which
the active drug moiety enters systemic circulation. Intravenous
administration has 100% bioavailability.
4. A patient with liver cirrhosis is prescribed a medication that
undergoes extensive first-pass metabolism. What should the NP
anticipate?
,A. A decreased therapeutic effect
B. An increased risk of toxicity
C. No change in drug response
D. Rapid excretion of the drug
Answer: B
Rationale: Cirrhosis impairs first-pass metabolism, leading to
higher plasma concentrations of the drug and an increased risk of
toxicity.
5. Which parameter reflects the time required for the plasma
concentration of a drug to decrease by 50%?
A. Onset of action
B. Duration of action
C. Half-life
D. Therapeutic index
Answer: C
Rationale: Half-life is the time it takes for the amount of drug in
the body to be reduced by one-half. It determines the dosing
interval.
6. A drug with a narrow therapeutic index requires:
A. Routine monitoring of serum drug levels
B. High doses to achieve therapeutic effect
C. No monitoring due to its safety profile
D. Administration without regard to timing
Answer: A
Rationale: A narrow therapeutic index means the difference
, between therapeutic and toxic doses is small. Serum levels must
be monitored to ensure safety and efficacy.
7. Which term refers to the ratio of the dose that produces
toxicity to the dose that produces a therapeutic effect?
A. Bioavailability
B. Therapeutic index
C. Half-life
D. Clearance
Answer: B
Rationale: The therapeutic index is a measure of drug safety. A
higher therapeutic index indicates a safer drug.
8. What is the primary focus of pharmacokinetics in drug therapy?
A. The study of drug effects on the body
B. The study of drug absorption, distribution, metabolism, and
excretion
C. The study of drug toxicity and adverse effects
D. The study of drug-receptor interactions
Answer: B
Rationale: Pharmacokinetics focuses on what the body does to
the drug—the processes of Absorption, Distribution, Metabolism,
and Excretion (ADME). Pharmacodynamics is what the drug does
to the body.
9. How does the first-pass effect influence oral drug
bioavailability?
